Track market-moving stories before they get noisy

Creative Medical Technology (NASDAQ:CELZ – Get Free Report) and CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Institutional and Insider Ownership 1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability This table compares Creative Medical Technology and CRISPR Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% CRISPR Therapeutics -3,368.72% -24.39% -18.25% Volatility and Risk Creative Medical Technology has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Valuation and Earnings This table compares Creative Medical Technology and CRISPR Therapeutics”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Creative Medical Technology $10,000.00 731.49 -$5.99 million ($2.07) -0.54 CRISPR Therapeutics $3.51 million 1,536.85 -$581.60 million ($4.76) -11.72 Creative Medical Technology has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations This is a breakdown of recent ratings and recommmendations for Creative Medical Technology and CRISPR Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 0 1 0 2.00 CRISPR Therapeutics 1 6 10 1 2.61 CRISPR Therapeutics has a consensus target price of $68.06, indicating a potential upside of 21.99%. Given CRISPR Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Creative Medical Technology.

Summary CRISPR Therapeutics beats Creative Medical Technology on 10 of the 15 factors compared between the two stocks.

(Get Free Report)

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About CRISPR Therapeutics (Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Receive News & Ratings for Creative Medical Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creative Medical Technology and related companies with MarketBeat.com's FREE daily email newsletter.

CRISPR Therapeutics (CRSP -1.88%) has already accomplished something most gene-editing companies are still trying to do: get a CRISPR-based medicine approved and onto the market. Now it has to prove it can build a business around the technology.

That starts with Casgevy, the gene-edited treatment for sickle cell disease developed with Vertex Pharmaceuticals (VRTX -3.21%). Casgevy generated $76 million in Q2 2026 revenue, up 78% sequentially and 151% year over year. It's now approved in 39 countries, and the FDA recently expanded its U.S. label to children as young as 2.

CRISPR Therapeutics receives 40% of Casgevy's profits and costs, while Vertex handles commercialization and manufacturing. That's a good foundation. But five years from now, I suspect Casgevy won't be the primary reason you'll want to own the stock.

The pipeline could become much more important The program I'm watching most closely is CTX310, which uses CRISPR to edit a gene called ANGPTL3 inside the body. If you're unfamiliar, ANGPTL3 helps regulate cholesterol and triglycerides, two major contributors to cardiovascular disease. And unlike Casgevy, which requires doctors to remove a patient's cells, edit them outside the body, and return them after intensive conditioning, CTX310 is delivered through a single intravenous infusion.

Image source: Getty Images.

The results have been impressive. At the highest dose tested in a phase 1 study, CTX310 produced average reductions of 53% in LDL cholesterol and 48% in triglycerides. Those effects were sustained through one year following a single treatment.

The numbers are encouraging, but this is still early-stage clinical research. CRISPR is currently evaluating CTX310 in phase 1b trials targeting severe hypertriglyceridemia and refractory hypercholesterolemia (two types of high blood fat levels). If those studies eventually show that one treatment can safely produce durable reductions in cholesterol and triglycerides, CTX310 could address a much larger population than Casgevy. And that's where this company starts getting really interesting.

There's more than one shot on goal CRISPR Therapeutics isn't betting everything on cardiovascular disease. Take Zugo-cel, formerly CTX112, an off-the-shelf CAR-T therapy being tested across autoimmune diseases and blood cancers. The company has trials underway in diseases including lupus, systemic sclerosis, multiple sclerosis, and several other autoimmune disorders.

Earlier results have provided some reason for optimism. In a small group of lymphoma patients receiving the 600-million-cell dose, Zugo-cel produced a 90% overall response rate and 70% complete response rate.

Premium Feature

Moneyball Superscore

55/100

Today's Change

(

-1.88

%) $

-1.05

Current Price

$

54.74

Then there's CTX340 for difficult-to-control high blood pressure, CTX460 for alpha-1 antitrypsin deficiency (a disorder that increases the risk of developing lung and liver disease), CTX611 for preventing blood clots, and CTX213, an experimental cell-replacement treatment for type 1 diabetes.

To be sure, not all of these programs will work. But they don't have to. If just two or three eventually become commercially successful medicines, CRISPR Therapeutics could look dramatically different by 2031.

The balance sheet buys plenty of time Biotech companies can have great pipelines and still destroy shareholders if they continually need to raise money. CRISPR Therapeutics is in a much better financial position.

The company finished June with approximately $2.36 billion in cash, cash equivalents, and marketable securities. That cash gives management plenty of room to advance multiple programs without immediately returning to shareholders for more capital.

CRISPR Therapeutics currently has a market capitalization of roughly $5.4 billion. With more than $2 billion in cash and one commercial product already on the market, you aren't paying an outrageous valuation for the pipeline. But you are paying for some success.

Where could the stock be in 2031? Predicting an exact share price for CRISPR Therapeutics five years out doesn't make much sense. There are just too many clinical trials between now and then. But the potential upside is substantial.

If Casgevy continues to gain adoption while CTX310 progresses into late-stage development and Zugo-cel demonstrates convincing efficacy in autoimmune disease, CRISPR Therapeutics could easily become a $10 billion to $15 billion company by 2031.

From today's roughly $5.4 billion valuation, that implies the potential for the stock to roughly double or even triple, although future dilution could reduce the per-share return. Indeed, the potential downside is not trivial. A major safety issue with in vivo gene editing or failures across CTX310 and Zugo-cel could erase a significant portion of the company's current valuation. That's why you shouldn't treat CRISPR Therapeutics like a conventional growth stock.

That said, Casgevy has already demonstrated that CRISPR can move from a laboratory concept to an FDA-approved medicine. The next five years will determine whether CRISPR Therapeutics could repeat that success across cardiovascular disease, autoimmune disorders, cancer, and other major diseases. If it can, today's $5.4 billion valuation could eventually look surprisingly cheap.

Should you invest in CRISPR Therapeutics (CRSP +0.18%) before the end of the year? The company's shares have slightly underperformed the broader market to date, but the biotech may see several catalysts that could send its share price jumping over the next four months. Here are two reasons why investors might want to consider loading up on CRISPR Therapeutics right now.

1. Casgevy's progress could be a welcome surprise Unlike most of its similarly sized peers that specialize in gene editing, CRISPR Therapeutics has launched a product, Casgevy, which earned approval in 2023. Casgevy treats two rare blood diseases: transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD). CRISPR Therapeutics collaborated with Vertex Pharmaceuticals (VRTX +1.66%) to develop it. Though the medicine was a breakthrough, it hasn't generated much sales yet. Here are two reasons why.

Image source: The Motley Fool.

First, ex vivo gene-editing therapies are challenging to administer. The process involves collecting patient cells, editing them, and reinserting them into the patient. It takes months to go through all these steps. Casgevy is also expensive. A single treatment course goes for $2.2 million in the U.S. Second, Casgevy's initial indication was fairly narrow. It was approved to treat patients with SCD and TDT aged 12 and older. CRISPR Therapeutics and Vertex just made progress with one of those issues.

Earlier this year, the U.S. Food and Drug Administration expanded Casgevy's label to include patients as young as two. This will allow CRISPR Therapeutics to target patients before TDT and SCD have caused them significant health problems. We shouldn't expect Casgevy's sales to soar later this year. But if CRISPR Therapeutics sees increased demand for the medicine and expands third-party coverage following the recent label expansion, that could meaningfully move the stock price.

2. Important clinical trial data readouts It's critical to keep an eye on Casgevy's progress, but CRISPR Therapeutics clinical work will be an even more important catalyst. The company should release data from several ongoing clinical trials by year-end. For instance, CRISPR Therapeutics is developing CTX611, a potential anticoagulant. CTX611 is one of the few candidates in CRISPR Therapeutics' portfolio that isn't a gene editing product.

Premium Feature

Moneyball Superscore

55/100

Today's Change

(

0.18

%) $

0.10

Current Price

$

56.92

CTX611 is an RNA-silencing medicine. Therapies of this kind work by "switching off" the instructions for making certain proteins involved in some conditions. In this case, CTX611 targets the Factor XI protein involved in blood clotting. Here's why it could be a breakthrough.

Whereas most anticoagulants are taken daily and carry a risk of severe bleeding, CTX611 is being developed to be administered twice a year and could also reduce the main side effects of its competitors. CRISPR Therapeutics is currently testing CTX611 in phase 2 clinical trials in patients who underwent total knee arthroplasty, a procedure that can lead to blood clots.

The company plans to release data from this study before the end of the year. Strong results could send CRISPR Therapeutics' share price soaring.

Mind your risk tolerance Strong progress with Casgevy and across CRISPR Therapeutics' pipeline could jolt the stock. However, there are significant risks. Clinical setbacks will obviously have the opposite impact. Still, my view is that CRISPR Therapeutics' prospects look somewhat attractive. The company has a reasonably deep pipeline for a biotech company of its size even beyond CTX611. It has already shown it can launch a gene-editing medicine, something that has proven challenging for others despite significant progress in the field.

Over the next few years, we could see CRISPR Therapeutics rack up enough clinical wins to expand its approved portfolio, and even the occasional setback -- which every biotech company experiences -- might not be too damaging, considering its deep pipeline. The stock should appeal to investors with above-average risk tolerance, who should consider initiating a position before the end of the year.

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-

-Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean reduction in triglycerides (TG) of 48% (maximum 78%), and a mean reduction of low-density lipoprotein (LDL) of 53% (maximum 84%) at the highest dose-

-CTX310 was well tolerated with no treatment-related serious adverse events, no ≥Grade 3 changes in liver transaminases, and no additional treatment-related adverse events since the previous update-

-Findings simultaneously published in The New England Journal of Medicine entitled “Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310”-

ZUG, Switzerland and BOSTON, Aug. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3. A single-course treatment with CTX310 produced deep and durable reductions in circulating ANGPTL3, triglycerides (TG), and low-density lipoprotein (LDL) that were sustained through one year of follow-up. At the highest dose, mean reductions from baseline were 79% (maximum 89%) for ANGPTL3, 48% (maximum 78%) for TG, and 53% (maximum 84%) for LDL. These extended follow-up data demonstrate the durability of CTX310's effect and support its potential to deliver long-lasting lipid lowering after a single intravenous (IV) infusion.

These data were presented today during a late breaking session at the European Society of Cardiology (ESC) Congress 2026 and extend the Phase 1 results previously presented. The data were also published today in The New England Journal of Medicine (NEJM) in a peer reviewed article entitled "Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310." CRISPR Therapeutics is advancing CTX310 in a Phase 1b clinical trial, with U.S. and ex-U.S. trials ongoing, and expects to provide an additional update on the CTX310 program in the second half of 2026.

"These durability data mark an important next step for the CTX310 program and for the field of in vivo gene editing," said Naimish Patel, M.D., Chief Medical Officer, CRISPR Therapeutics. "Evidence that a single dose can produce lasting lipid lowering is central to our goal of developing one-time treatments for cardiometabolic diseases. These results provide strong support for continued advancement of CTX310 and our broader cardiovascular gene editing portfolio, and we look forward to sharing new data from the severe hypertriglyceridemia cohort of the CTX310 Phase 1b trial in the second half of this year."

"For patients at high cardiovascular risk, the biggest challenge is often not starting therapy but staying on it, since daily medications require lifelong adherence that many patients are unable to maintain," said Luke Laffin, M.D., principal investigator and Medical Director of the Cleveland Clinic Coordinating Center for Clinical Research. "A single infusion producing durable reductions at one-year is an encouraging signal that a one-time approach could help close that adherence gap."

"What is compelling about this update is that the reductions in ANGPTL3, triglycerides, and LDL from a single infusion have persisted out to one-year, suggesting a sustained biological effect," said Steven E. Nissen, M.D., senior author of the study and Chief Academic Officer at the Cleveland Clinic Heart, Vascular and Thoracic Institute. "A one-time treatment with this degree of durability could represent a meaningful advance in how we manage lifelong lipid disorders."

Phase 1a Clinical Trial Design

The Phase 1a portion of the study was an open label, dose-escalation trial evaluating single-course IV doses of CTX310 ranging from 0.1 to 0.8 mg/kg (lean body weight) targeting ANGPTL3 in four patient groups: homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (sHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias (elevated TG and LDL). Eligible participants had uncontrolled TG levels >150 mg/dL and/or LDL cholesterol >100 mg/dL (or >70 mg/dL for those with established ASCVD) despite background standard of care per local guidelines.

The majority of participants were receiving statins and/or ezetimibe, while 40% were taking PCSK9 inhibitors. The trial was designed to evaluate safety and tolerability as primary endpoints, with changes in circulating ANGPTL3 protein, TG, and LDL as secondary endpoints.  

Safety and Tolerability

Single-course ascending doses of CTX310 were administered to 15 participants across sequential cohorts, and all participants completed at least one-year of follow-up as of the data cutoff. CTX310 was generally well tolerated, and no dose-limiting toxicities or serious adverse events related to treatment. Adverse events were generally mild to moderate.

As previously reported in Laffin et al. (2025), one participant experienced an allergic reaction that resolved the following day with supportive care. Infusion-related reactions occurred in three participants (two at 0.6 mg/kg and one at 0.8 mg/kg dose), all Grade 2. All events resolved, and all participants completed their infusions. Beyond the transient aminotransferases elevation previously reported in one participant shortly after treatment, there were no liver function test elevations throughout the remainder of the trial.

The safety events described above were previously reported in Laffin et al. (New England Journal of Medicine, 2025) and reflect the initial treatment period of the Phase 1a clinical trial. No new treatment-related safety events were observed during extended follow-up.

Efficacy Highlights

These new results build upon previously disclosed clinical data from 15 participants across four sequential cohorts, corresponding to lean body weight-based doses of DL1 [0.1 mg/kg], DL2 [0.3 mg/kg], DL3 [0.6 mg/kg], DL3.5 [0.7 mg/kg] and DL4 [0.8 mg/kg]. All participants had at least one-year of follow-up.

Dose dependent reductions in circulating ANGPTL3 protein were sustained through one-year following CTX310 infusion.Among participants treated at 0.8 mg/kg, ANGPTL3 reductions of up to 89% were observed, with a mean reduction of 79% at one-year following CTX310 infusion. Next Steps

The Phase 1b portion of the trial examines a fixed flat dose regimen of CTX310 equivalent to the most efficacious dose in Phase 1a (0.8mg/kg). CRISPR Therapeutics continues to anticipate sharing an update from the CTX310 Phase 1b clinical trial in the second half of 2026, focused on severe hypertriglyceridemia patients.

About In Vivo Liver Editing Programs

CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase™ editing technology. The Company's in vivo portfolio includes three cardiovascular programs: CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340™, targeting angiotensinogen (AGT), in development for refractory hypertension; and CTX321™, targeting LPA, in development for patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company's disclosed development candidates also include CTX460™, targeting SERPINA1 using SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).

About CRISPR Therapeutics

CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS® standard character mark and design logo, CTX310®, CTX321™, CTX340™, CTX460™ and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Reference

Laffin L, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. The New England Journal of Medicine. 2025.
CRISPR Special Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described oral presentation and any associated abstracts or posters, data included in the above-described article in The New England Journal of Medicine, as well as the ability to use data from ongoing and planned clinical trials for the design and initiation of further clinical trials; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact: 
+1-617-307-7503 
[email protected]

Media Contact: 
+1-617-315-4493 
[email protected]

Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.

Key Takeaways CRSP's Q2 loss of 94 cents per share was narrower than estimated. Revenues too topped expectations.CRSP benefits from rising Casgevy uptake as Vertex posted 78% sequential sales growth in Q2 2026.CRSP ended June with $2.36 billion in cash supporting pipeline expansion and multiple updates for H2 2026. CRISPR Therapeutics (CRSP - Free Report) incurred second-quarter 2026 loss of 94 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.10. The company had incurred a loss of $2.40 in the year-ago quarter.

Total revenues were $10.2 million in the second quarter (comprising $10 million in collaboration revenue and the rest from grant revenues), which also beat the Zacks Consensus Estimate of $7 million. In the year-ago period, CRSP had recorded total revenues of $0.89 million, which comprised only grant revenues.

Year to date, shares of CRISPR Therapeutics have lost 5.4% while the industry has risen 2.8%.

Image Source: Zacks Investment Research

CRSP Boasts Robust Casgevy Sales MomentumCRISPR Therapeutics and partner Vertex Pharmaceuticals’ (VRTX - Free Report) CRISPR/Cas9 gene therapy, Casgevy, is approved across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Per the deal terms, Vertex leads global development, manufacturing and commercialization of Casgevy and splits program costs and profits worldwide with CRISPR Therapeutics in a 60:40 ratio.

The FDA recently approved Casgevy for use in children aged two years and older with SCD or TDT. Regulatory filings were also completed in Saudi Arabia and the United Kingdom for children aged five to 11 years. In May, Vertex secured reimbursement in Germany for eligible patients aged 12 years and older.

Vertex recorded Casgevy sales of $76 million in the second quarter of 2026. Sales increased 78% sequentially and 151% year over year, reflecting continued commercial uptake.

CRISPR Therapeutics Controls Quarterly CostsResearch and development expenses were $67.2 million in the second quarter, down 3.9% year over year. The decline primarily reflected lower employee and facility-related expenses, partly offset by higher license fees.

General and administrative expenses declined 6.9% to $17.6 million, mainly due to lower employee-related costs, including stock-based compensation. Collaboration expense, net, fell 10.8% to $40.3 million, driven by an increase in CRSP’s share of Casgevy revenues under the Vertex collaboration economics.

Acquired in-process research and development expenses were $2.5 million compared with $96.3 million in the year-ago quarter. The prior-year amount reflected costs related to the company’s agreement with Sirius Therapeutics.

CRSP exited June with $2.36 billion in cash, cash equivalents and marketable securities, down from $2.44 billion at the end of March 2026. The sizeable cash position provides CRISPR Therapeutics with resources to support commercialization activities and advance its diversified clinical pipeline. Multiple clinical updates are expected during the second half of 2026.

CRSP’s Pipeline UpdatesCRISPR Therapeutics continues to prioritize CTX310, an investigational gene-editing therapy targeting ANGPTL3. The candidate is advancing in a phase Ib study for severe hypertriglyceridemia and refractory hypercholesterolemia, with U.S. studies initiated and ex-U.S. studies ongoing. An update on this study is expected in the second half of 2026.

CRSP initiated a phase I study of CTX340 in patients with refractory hypertension after receiving FDA clearance. It also started a phase I study of CTX460 for treating alpha-1 antitrypsin deficiency.

The preclinical CTX321 program, which targets elevated lipoprotein(a), is progressing through investigational new drug and clinical trial application-enabling studies. An update is expected later in 2026.

Zugo-cel, CRSP’s allogeneic CAR-T candidate, is being evaluated across autoimmune diseases and blood cancers. Two ongoing phase I autoimmune basket studies cover rheumatology indications and hematologic disorders, including systemic lupus erythematosus, systemic sclerosis, inflammatory myositis, immune thrombocytopenic purpura and warm autoimmune hemolytic anemia.

A third phase I study has begun targeting various autoimmune neurologic diseases. Enrollment continues across the broader autoimmune program, with additional updates expected in the second half of 2026.

In immuno-oncology, the phase I/II study of zugo-cel in B-cell malignancies remains underway. CRSP is also evaluating zugo-cel with Eli Lilly’s Jaypirca (pirtobrutinib) in aggressive B-cell lymphomas. Several updates are expected in the second half of 2026.

The company’s siRNA candidate, CTX611, is advancing in a phase II study for patients undergoing total knee arthroplasty (TKA). CRSP expects to provide an update in the second half of 2026.

CRSP’s Zacks Rank & Stocks to ConsiderCRISPR Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 10.2% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 143.1% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.

Are you hoping for a better performance from your portfolio in the latter half of this year than you achieved during the first half? It may require a slightly different selection of stocks.

Here's a closer look at three of the market's better-known names with more near-term upside than most other tickers. Namely, each of these stocks is currently priced well below analysts' consensus, although there's far more working in their favor than just this relative discount.

CRISPR Therapeutics Shares of gene-editing drug specialist CRISPR Therapeutics (CRSP +1.68%) have been stuck in neutral since 2022. Although its first-ever approved drug Casgevy works well enough as a therapy for sickle cell disease, since each patient's treatment is custom-built, it can take several months -- even up to a year -- to complete the process.

The treatment's seven-figure price tag may also be slowing things down. That's why the company hasn't actually reported any real product revenue yet, despite the drug's late-2023 approval.

Today's Change

(

1.68

%) $

0.80

Current Price

$

48.44

It's coming. though. As of the first quarter, over 500 people have begun the Casgevy treatment process, prompting analysts to expect $40 million worth of revenue this year, en route to over $160 million in sales next year. Simply moving in the right direction could get buyers off the sidelines and into the stock.

Analysts collectively say this ticker is worth $83.53 per share, up 75% from its present price.

Microsoft It's been a miserable past 12 months for Microsoft (MSFT +15.51%) shareholders. The stock's down 25% from last August's peak, mostly due to worries over the company's slowing cloud computing (and AI) business.

Image source: Getty Images.

All this trouble, however, is arguably already priced into this stock (and then some), at a point when CEO Satya Nadella finally appears willing to acknowledge it, and then do something about it. The company announced in early July that it would be laying off nearly 5,000 employees, with a big piece of that reduced headcount coming from its soon-to-be-overhauled Xbox unit. Look for similar evolutions going forward, too.

Analysts seem to be expecting them, anyway, with a turnaround from the stock to soon follow. Their 12-month consensus price target of $554.77 is more than 40% above Microsoft shares' price right now.

Today's Change

(

15.51

%) $

60.56

Current Price

$

451.10

Recursion Pharmaceuticals Finally, add Recursion Pharmaceuticals (RXRX +2.36%) to your list of stocks with a great deal of near-term upside. Analysts say it's worth an average of $7.25 per share, or over 100% more than the ticker's current price.

It's not a pharmaceutical company in the traditional sense. Rather, it's a technology company that's built an artificial intelligence platform to virtually test how a particular drug molecule might perform as a treatment for a particular disease. It doesn't replace clinical testing, but it does help determine what's worth pursuing, and what isn't.

Today's Change

(

2.36

%) $

0.07

Current Price

$

3.04

So far, its business has been modest -- mostly upfront or milestone payments, and grants. Some of its drug developments are within sight of late stages, like the cancer drugs it helped Sanofi figure out. Meanwhile, look for updates on its own polyp-fighting REC-4881 and oncology drug REC-1245 later this year and/or early next year.

With the proverbial endzone in sight, investors soon might start taking interest in this stock again.

CRISPR Therapeutics AG (CRSP - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this company have returned -17.1% over the past month versus the Zacks S&P 500 composite's +1.7% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has lost 3% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

CRISPR Therapeutics is expected to post a loss of $1.10 per share for the current quarter, representing a year-over-year change of +14.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.8%.

For the current fiscal year, the consensus earnings estimate of -$4.9 points to a change of +24.3% from the prior year. Over the last 30 days, this estimate has changed -0.3%.

For the next fiscal year, the consensus earnings estimate of $4.18 indicates a change of +14.7% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed +6.4%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For CRISPR Therapeutics, the consensus sales estimate for the current quarter of $7.42 million indicates a year-over-year change of +733.3%. For the current and next fiscal years, $28.88 million and $135.51 million estimates indicate +722.8% and +369.2% changes, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago.

Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

In the latest close session, CRISPR Therapeutics AG (CRSP - Free Report) was down 2.08% at $46.54. This move lagged the S&P 500's daily gain of 0.05%. At the same time, the Dow added 0.46%, and the tech-heavy Nasdaq lost 0.64%.

The company's shares have seen a decrease of 11.95% over the last month, not keeping up with the Medical sector's gain of 3.64% and the S&P 500's gain of 0.61%.

The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. The company is expected to report EPS of -$1.1, up 14.73% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $7.42 million, reflecting a 733.26% rise from the equivalent quarter last year.

CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.9 per share and revenue of $28.88 million. These results would represent year-over-year changes of +24.27% and +722.82%, respectively.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.26% lower within the past month. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 91, finds itself in the top 37% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,853,875 shares of the company’s stock after selling 104,236 shares during the quarter. CRISPR Therapeutics comprises approximately 1.2% of Amova Asset Management Americas Inc.’s holdings, making the stock its 26th biggest holding. Amova Asset Management Americas Inc. owned approximately 1.92% of CRISPR Therapeutics worth $88,189,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in CRSP. Hollencrest Capital Management increased its holdings in shares of CRISPR Therapeutics by 249.9% during the 1st quarter. Hollencrest Capital Management now owns 1,312 shares of the company’s stock worth $62,000 after buying an additional 937 shares during the last quarter. KBC Group NV boosted its holdings in CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after acquiring an additional 113,997 shares during the last quarter. Swiss National Bank grew its position in CRISPR Therapeutics by 5.1% during the first quarter. Swiss National Bank now owns 169,700 shares of the company’s stock valued at $8,073,000 after acquiring an additional 8,200 shares during the period. Allspring Global Investments Holdings LLC grew its position in CRISPR Therapeutics by 11.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,932 shares of the company’s stock valued at $290,000 after acquiring an additional 605 shares during the period. Finally, Independent Financial Group LLC acquired a new stake in CRISPR Therapeutics during the first quarter worth about $292,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at CRISPR Therapeutics In related news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total transaction of $210,577.32. Following the sale, the insider owned 19,357 shares of the company’s stock, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.20% of the stock is owned by company insiders.

CRISPR Therapeutics Stock Down 1.7% NASDAQ CRSP opened at $46.99 on Tuesday. The company has a quick ratio of 17.96, a current ratio of 17.97 and a debt-to-equity ratio of 0.32. CRISPR Therapeutics AG has a fifty-two week low of $44.12 and a fifty-two week high of $78.48. The business has a 50 day moving average price of $52.96 and a two-hundred day moving average price of $52.88. The stock has a market cap of $4.53 billion, a PE ratio of -7.55 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -4.9 EPS for the current fiscal year.

Analysts Set New Price Targets A number of equities analysts have recently commented on the company. Wall Street Zen downgraded CRISPR Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 5th. Citizens Jmp reissued a “market outperform” rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Friday. Evercore reaffirmed an “outperform” rating and set a $76.00 price target on shares of CRISPR Therapeutics in a research report on Monday, May 11th. Finally, UBS Group set a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 12th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $67.78.

Check Out Our Latest Report on CRISPR Therapeutics

About CRISPR Therapeutics (Free Report)

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

Featured Articles Five stocks we like better than CRISPR Therapeutics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Sells 1,847 Shares of Vanguard Small-Cap ETF $VB

NEXT HEADLINE »10x Genomics $TXG Shares Sold by Amova Asset Management Americas Inc.

In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $47.78, marking a -1.63% move from the previous day. This change lagged the S&P 500's 1.01% loss on the day. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%.

Shares of the company have depreciated by 10.21% over the course of the past month, underperforming the Medical sector's gain of 5.37%, and the S&P 500's gain of 0.32%.

Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$1.1, marking a 14.73% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 million, showing a 733.26% escalation compared to the year-ago quarter.

For the annual period, the Zacks Consensus Estimates anticipate earnings of -$4.9 per share and a revenue of $28.88 million, signifying shifts of +24.27% and +722.82%, respectively, from the last year.

It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.26% lower within the past month. As of now, CRISPR Therapeutics AG holds a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 93, putting it in the top 38% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.

CRISPR Therapeutics AG (CRSP - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned -3.8%, compared to the Zacks S&P 500 composite's +1.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 3.6%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

CRISPR Therapeutics is expected to post a loss of $1.10 per share for the current quarter, representing a year-over-year change of +14.7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of -$4.89 for the current fiscal year indicates a year-over-year change of +24.4%. This estimate has changed -0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $3.97 indicates a change of +18.8% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of CRISPR Therapeutics, the consensus sales estimate of $7.42 million for the current quarter points to a year-over-year change of +733.3%. The $28.88 million and $131.2 million estimates for the current and next fiscal years indicate changes of +722.8% and +354.3%, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago.

Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

CRISPR Therapeutics (CRSP 4.99%) has significantly underperformed broader equities over the past five years. Some will argue the company's value -- its market cap is $5.7 billion as of writing -- is still too high given the fundamentals of the business. CRISPR Therapeutics generates little revenue, is consistently unprofitable, and hasn't earned significant late-stage clinical wins over the past couple of years. However, despite all that, CRISPR Therapeutics could be an attractive buy-and-hold option. Let's consider three reasons why the biotech is worth serious consideration.

1. Multiple catalysts on the way CRISPR Therapeutics specializes in developing gene editing therapies. This technology has already helped unlock groundbreaking medicines for otherwise difficult-to-treat conditions. However, we are arguably still in the early innings of the gene-editing revolution in the biotech industry, as the U.S. Food and Drug Administration has approved only a few treatments of this kind. But thanks to its potential to transform standards of care across many therapeutic areas, it's worth investors' time to look for the best gene-editing-focused companies. CRISPR Therapeutics fits the bill.

Image source: The Motley Fool.

The biotech's lineup features several promising candidates that could make significant progress over the next few years, jolting its stock price. Consider CRISPR Therapeutics' CTX310, an investigational one-time treatment designed to permanently lower LDL cholesterol by switching off the ANGPTL3 gene (which helps regulate cholesterol) in the liver, helping the body remove harmful fats from the bloodstream more effectively. If it proves safe and effective, it could transform care by replacing lifelong cholesterol drugs with a one-time treatment. With millions of people at high risk of heart disease (and other cardiovascular conditions) due to high cholesterol levels, CTX310 has a potentially large commercial opportunity.

CRISPR Therapeutics plans on releasing results from an ongoing clinical trial of CTX310 during the second half of the year. Positive data could send CRISPR Therapeutics' shares soaring. And that's just the tip of the iceberg. CRISPR Therapeutics has other promising candidate that should also make progress in the next few years. The biotech's strong, gene-editing-focused pipeline makes the stock attractive, as the company's breakthrough could lead to highly effective treatments and significant commercial success.

2. Casgevy's large opportunity CRISPR Therapeutics has already shown it can secure approval for a gene-editing medicine. It did so with Casgevy, a therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals (VRTX 2.07%). This may seem trivial, but the fact is that many (perhaps most) of CRISPR Therapeutics' peers -- that is, biotechs that specialize in gene editing -- have yet to earn approval for a single one of their candidates. Also, Casgevy's milestone was all the more impressive because it was the first CRISPR-based gene-editing therapy to receive regulatory approval.

Today's Change

(

-4.99

%) $

-2.81

Current Price

$

53.53

Casgevy has not yet generated much revenue, but that could change soon. CRISPR Therapeutics and Vertex Pharmaceuticals recently announced that the U.S. Food and Drug Administration had approved the medicine for children as young as two (it was previously indicated for people aged 12 and older). This label expansion adds 5,500 patients to Casgevy's addressable market in the country.

That may not seem like a lot, but at $2.2 million per treatment course, that's an additional $12.1 billion commercial opportunity, and that's only in the U.S. (Vertex and CRISPR Therapeutics share the earnings from Casgevy, with the latter getting 40% of the profits). Casgevy won't capture this entire market on its own, but the medicine's sales should ramp up over the next few years, helping boost CRISPR Therapeutics' financial results.

3. Expanding beyond gene editing Although gene editing remains CRISPR Therapeutics' core focus, the company has branched out into other areas. The biotech partnered with Sirius Therapeutics, a privately held company, to develop CTX611, a small-interfering RNA (siRNA) therapy. Unlike gene-editing medicines that alter the DNA sequence, siRNA medicines "silence" genes responsible for certain diseases, though the effect is temporary, and these therapies need to be readministered.

CTX611 is a long-acting siRNA therapy designed to prevent dangerous blood clots while causing less bleeding than today's anticoagulants. If approved, its potential for just two injections per year could make it a transformative treatment and a multibillion-dollar commercial success. Just as important, CRISPR Therapeutics is showing that it isn't just a gene editing company. The biotech is willing to pursue attractive opportunities in other fields.

Read the fine print A lot could still go wrong with CRISPR Therapeutics, particularly significant clinical setbacks for its most promising candidates. The company's commercial opportunity with Casgevy could also fail to materialize. These are all risks investors should keep in mind. However, given its partnership with a biotech giant to commercialize Casgevy and its deep (and innovative) pipeline, CRISPR Therapeutics looks likely to significantly expand its approved product portfolio and improve its financial results by the end of the decade. The stock may offer outstanding returns along the way.

Like most other up-and-coming biopharma companies, CRISPR Therapeutics (CRSP 2.10%) brings both risk and reward to the table. This particular name, however, may bring less risk than it seems at first blush, and perhaps even more reward.

CRISPR Therapeutics is different from most of its kind CRISPR Therapeutics is a developer of gene therapies for disease, by the way. Specifically, the company's founders figured out how to cut a damaged segment out of a DNA strand and replace it with a corrected one. It even has an approved therapy on the market, with more in the works.

As you might imagine, though, such development isn't cheap. Like other newcomers to the biopharma business, CRISPR Therapeutics is consuming cash at a pretty brisk clip.

Image source: Getty Images.

However, it's different from most others of this ilk. Unlike its similarly sized and similarly aged peers, this $5.9 billion outfit is sitting on $2.4 billion worth of cash and marketable securities that can be readily converted into cash if and when the need arises. At its current rate of cash burn, that's a little over four years' worth of funding without the need for any additional, dilutive fund-raising.

This essentially means the company's science, research, and future are currently valued at only about $3.5 billion, or only around $3 billion after factoring in debt.

The stock price reflects too much risk with not enough reward Granted, CRISPR Therapeutics needs at least some of its current research and development pipeline to result in drug approvals to justify any valuation. And to raise money, the company has issued stock and convertible notes before, which of course was dilutive.

Today's Change

(

-2.10

%) $

-1.30

Current Price

$

60.59

All of this is already priced into the stock, though, and won't need to happen again anytime soon -- if ever. See, CRISPR Therapeutics has the potential to generate its own self-sustaining funding within just a few years. The odds of this happening aren't reflected in the current share price.

Analysts don't think so, anyway. Their current consensus price target of $81.10 is 35% above the price right now.

CRSP weekly chart shows completion of bearish correction within long-term bull trend

Next Resistance Could Unlock Trend Reversal Friday’s advance confirmed breakouts from both bottoming patterns, with initial resistance seen near the February swing high of $61.76. Once that February high is decisively recovered, another bullish signal would be triggered, as that would indicate that the prior intermediate downtrend has reversed. It would also provide further confirmation that the broader bottoming process has completed, signaling the beginning of a new leg higher within the long-term bull trend.

Measured Move Targets Extend Bullish Outlook CRSP reached a high of $78.48 in October 2025, completing a 54.5% gain from the prior swing low recorded in September. Projecting a similar measured move from the March low of $44.12 points to a potential upside target near $67.94. In addition, the inverse head and shoulders pattern projects upside objectives of approximately $75.61 using a traditional price objective or $81.18 using an equivalent percentage advance. Those targets reinforce the significance of the recent breakout and suggest it could mark the early stages of a larger bullish trend reversal, provided the breakout continues to hold.

If you’d like to know more about technical analysis and how traders use it, please visit our educational area.

Choosing between Arcutis Biotherapeutics (ARQT 0.12%) and Vertex Pharmaceuticals (VRTX +6.13%) involves weighing a high-growth newcomer against a cash-generating giant. Both companies aim to dominate their respective niches within the healthcare sector.

Arcutis focuses on topical treatments for common skin conditions, aiming to disrupt the competitive dermatology market with innovative creams. Vertex is a global leader in treating rare diseases, recently diversifying its portfolio beyond its core cystic fibrosis treatments. Both companies represent different risk-reward profiles for investors targeting the biotech space.

The case for Arcutis BiotherapeuticsArcutis Biotherapeutics is a commercial-stage medical dermatology company that develops and sells topical therapies for immune-mediated skin diseases. Its primary commercial strategy centers on the Zoryve product line, which includes treatments for plaque psoriasis and atopic dermatitis. To reach patients, the company relies on a network of specialty pharmacies and maintains strategic licensing agreements with AstraZeneca (AZN +6.04%) and Jiangsu Hengrui Medicine.

In FY 2025, revenue reached nearly $376.1 million, representing a massive 101% growth over the prior year. Despite this rapid expansion, the company reported a net loss of $16.1 million. This net loss is a significant improvement over the prior year’s $140 million loss, suggesting the company is effectively scaling its revenue relative to its fixed costs.

On its current balance sheet, the debt-to-equity ratio is close to 0.7x, showing a strong ability to cover short-term liabilities with current assets. Free cash flow was a negative $6.3 million as the business continues to invest in its growth within the biotech stocks landscape.

The case for Vertex PharmaceuticalsVertex Pharmaceuticals is a global biotechnology leader primarily known for its dominance in treating cystic fibrosis. The company derives nearly all of its product revenue from medicines like Trikafta, which it distributes through a limited number of specialty pharmacy networks. It also maintains key strategic collaborations with CRISPR Therapeutics (CRSP +7.77%) and Moderna (MRNA +9.99%) to develop new therapies for serious diseases like sickle cell disease.

In FY 2025, revenue reached $12 billion, representing a year-over-year increase of nearly 10%. The company reported net income of nearly $4 billion, resulting in a net margin of approximately 32.7%. Net margin indicates how much of every dollar in revenue actually becomes profit after all expenses, and the company's P/S ratio, which compares its stock price to its total sales, reflects its market standing.

Its current debt-to-equity ratio is approximately 0.1x. This ratio compares total debt to shareholder equity, and a lower number indicates a conservative approach to borrowing. Free cash flow for FY 2025 was close to $3.2 billion. Free cash flow is the cash a company generates after accounting for the money spent to maintain or expand its asset base.

Risk profile comparisonArcutis Biotherapeutics faces substantial risks stemming from its reliance on the Zoryve product line in a competitive field dominated by giants like AbbVie (ABBV +3.90%) and Pfizer (PFE +1.84%). Additionally, the company is involved in patent litigation with Teva Pharmaceutical Industries (TEVA +3.59%) regarding generic versions of its flagship cream. Failure to protect its intellectual property or meet financial covenants with SLR Investment Corp (SLRC 0.72%) could significantly harm its operations.

Vertex Pharmaceuticals deals with heavy revenue concentration, as its cystic fibrosis franchise accounts for the vast majority of its sales. This makes the company vulnerable to competitive entry and ongoing pricing pressure from government cost-containment measures like the Inflation Reduction Act. Clinical development also carries inherent risks, as illustrated by a recent class-action investigation into results from a Phase 2b trial.

Valuation comparisonVertex Pharmaceuticals offers a lower Forward P/E, but Arcutis Biotherapeutics has a lower P/S ratio compared to its peer.

MetricArcutis BiotherapeuticsVertex PharmaceuticalsSector BenchmarkForward P/E142.86x26.1x389.1xP/S ratio8.0x10.5xSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Arcutis has just reached positive cash flow in its first quarter of fiscal 2026, with sales up 65% from the first quarter of 2025 but down 16% sequentially. This stems from the fact Zoryve isn’t a must-have for most patients, so its demand appeared impacted by higher consumer costs from rising gas prices and food inflation. The company discounts the product price, covers the copay if the patient has insurance, and charges $35 if they don’t. Demand for Zoryve also seems to be driven by the weather, with demand weaker when the weather doesn’t trigger as many skin conditions.

The cash-flow positive quarter means the business does have the capital to start to invest more in marketing and promoting Zoryve. Research and development efforts should lead to more indications that Zoryve can treat, too. Wall Street sees revenue rising 26% this year to $497 million, with the business registering its first annual net income.

Vertex, meanwhile, is building on its dominant position in cystic fibrosis treatment by investing heavily in research and development. In the past couple of years, Vertex has expanded its CF drug treatments. Its products now address 95% of all CF patients in the U.S. Approvals in other markets are coming through, which means the market for its existing drugs continues to expand. Vertex is also deep in trials for a drug to treat conditions that lead to renal failure, a new market for Vertex. The U.S. has accelerated approval for povetacicept in IgA nephropathy, a treatment that would be a blockbuster ($1 billion-plus in lifetime sales) if approved.

Arcutis is an interesting business that is just getting off the ground. Yet Arcutis’ main product does not fill a high-priced niche and appears subject to seasonality and fluctuations in consumer demand, which should give an investor pause.

Vertex continues to be a fast grower too, with Wall Street seeing sales grow more than $1 billion this year to over $13 billion, with nearly $4.5 billion in net income. With an expanding market, heavy R&D, and a decent price-to-forward earnings ratio, Vertex gets the nod.

Deciding between CRISPR Therapeutics AG (CRSP +1.74%) and Vertex Pharmaceuticals (VRTX +2.31%) involves weighing high-growth gene-editing potential against a profitable, established leader. Both companies currently partner on breakthrough therapies but offer different investor profiles.

CRISPR Therapeutics focuses on transformative gene-based medicines, while Vertex dominates the cystic fibrosis market and generates substantial cash flow. They share the profits of their joint gene-editing therapy, CASGEVY. This comparison evaluates their financial health, risk factors, and current valuations to help you decide which fits your portfolio strategy better.

CRISPR Therapeutics AG focuses on creating transformative medicines through its proprietary gene-editing platform. Its flagship product is CASGEVY, a therapy developed for sickle cell disease and transfusion-dependent beta thalassemia. The company relies heavily on its partnership with Vertex Pharmaceuticals, sharing profits and losses at a 40% to 60% split. This customer concentration adds a layer of risk to the business since the company maintains limited internal commercial infrastructure and relies on the global footprint of its partner.

In FY 2025, revenue reached nearly $3.5 million, representing a decline of roughly 90.0% compared to the prior year. This decrease occurred as the company transitioned through different stages of milestone recognition and commercial rollout. The company reported a net loss of approximately $581.6 million for the period, reflecting the heavy investment required for its clinical pipeline. High net losses are typical for biotech stocks pursuing groundbreaking medical advancements.

According to its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.2x. This indicates that the company has a low level of total debt compared to the equity held by shareholders. The current ratio, which measures the ability to pay short-term obligations with short-term assets, is approximately 13.3x. Free cash flow was negative at nearly $345.9 million, as the company prioritized research over cash generation.

The case for Vertex PharmaceuticalsVertex Pharmaceuticals provides essential treatments for serious diseases, primarily dominating the global market for cystic fibrosis therapies. Its portfolio includes widely used medicines like TRIKAFTA and ALYFTREK, alongside its newer acute pain medication, JOURNAVX. The company operates through a global distribution network of wholesalers and specialty pharmacies. It also leads the commercialization of CASGEVY in its partnership with CRISPR Therapeutics AG.

For FY 2025, the company generated revenue of close to $12 billion, a year-over-year increase of roughly 8.9%. Net income reached approximately $4.0 billion, demonstrating the company's ability to maintain high profitability from its established drug portfolio. The net margin was roughly 32.7%, illustrating the significant portion of revenue that remains after all expenses are paid. These figures highlight a mature business model with steady cash inflows and consistent growth.

As of its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.4x. A low ratio suggests the company is not overly dependent on borrowed money to fund its operations. The current ratio stands at roughly 2.9x, indicating a healthy margin of safety for meeting short-term financial commitments. Free cash flow, calculated as cash from operations minus capital expenditures, was strong at nearly $3.2 billion.

Risk profile comparisonCRISPR Therapeutics AG faces significant hurdles regarding its financial sustainability, having incurred substantial operating losses that require frequent capital raises. One such raise included a $600 million convertible note issuance in Q1 2026. The company also faces intellectual property litigation from ToolGen, which alleges patent infringement by its core gene-editing technology. Furthermore, any disruption in its relationship with its primary partner could materially harm its commercial prospects and long-term viability.

Vertex Pharmaceuticals deals with heavy revenue concentration, as the vast majority of its sales come from its cystic fibrosis portfolio. This makes the business vulnerable to new competitive launches or regulatory actions affecting those specific drugs. Clinical setbacks, such as the RewinD-LB trial failure, remind investors of the inherent risks in drug development. Additionally, the company faces pressure from federal initiatives like the Inflation Reduction Act and legal arbitration with the Cystic Fibrosis Foundation over royalty costs.

Valuation comparisonVertex Pharmaceuticals trades at a lower revenue multiple than its younger peer, though its earnings valuation sits closer to the broader sector average.

MetricCRISPR Therapeutics AGVertex PharmaceuticalsSector BenchmarkForward P/E18.6x25.3x24.6xP/S ratio1270x10xn/aSector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?These two stocks require completely different investor mindsets, and the choice between them is less about which is better and more about what you're trying to do. Vertex is a profitable, cash-generating business with a dominant market position and a pipeline expanding beyond cystic fibrosis. It rewards patience without demanding it — the kind of stock that quietly compounds while you're watching something else. CRISPR is a different proposition entirely. You're betting on a technology platform still proving itself, with real clinical shots on goal but no earnings and a long road to commercial independence. The upside is asymmetric if the pipeline delivers; so is the downside if it doesn't. An investor who wants durable healthcare exposure without binary outcomes owns Vertex. A risk-tolerant investor with a long horizon and conviction in gene editing has a case for CRISPR. And if you want both ends of the spectrum, together they form a natural barbell for a healthcare allocation — a profitable compounder paired against a high-risk platform bet.

If you're getting started with investing or want ideas on which stocks could be good buys in today's market, let me walk you through how I'd invest $10,000 today.

What I think is important is to create some strong pillars in your portfolio, around blue chip stocks that you don't have to worry about. This gives you a good base and foundation where you put the bulk of your money into. This is likely where you'll also want to have some dividend income, just to pad your returns or generate valuable cash flow (should you decide not to reinvest the dividends). And after doing this, you can then take on some risk and potentially capitalize on lucrative opportunities in the long run.

Here's how I'd allocate $10,000 using this approach.

Image source: Getty Images.

I'd put $6,000 into a top dividend stock For a rock-solid base to build around, I'd pick Enbridge (ENB +0.15%) stock. The company has been growing its dividend for decades, has a stable, consistent pipeline business, and already offers a fairly high yield of 5%. It's an absolute gem in the oil and gas sector, yet it doesn't come with the risk that often accompanies these types of stocks. Since it's involved in infrastructure and transporting oil and gas, it's a much safer all-around investment to consider.

Today's Change

(

0.15

%) $

0.08

Current Price

$

54.55

This year, the stock has performed particularly well, up 16%, as investors have been loading up on oil and gas stocks amid rising commodity prices. But Enbridge is a solid stock to own, regardless of the price of oil. It has averaged a beta of 0.81 over the past five years, indicating that it's less volatile than the overall stock market. With a safe dividend and a robust business, I'd feel comfortable investing $6,000 in the stock, which, based on the current yield, would produce about $300 in dividends per year.

I'd invest $3,000 into an excellent growth stock As part of a long-term growth strategy, I'd also want to put a fair bit of money into a promising growth stock. But I don't want to put my money at risk and throw it at just any growth stock. Instead, I'd put it in a leading company such as Alphabet (GOOG +1.58%)(GOOGL +1.29%).

Alphabet stands out for its diversification and financial strength. Between YouTube, Google Search, Gemini, and Waymo, the company has promising assets that can drive growth for years to come. It offers the type of diversification you might crave in an exchange-traded fund, yet you get it through a single stock.

Today's Change

(

1.58

%) $

5.72

Current Price

$

367.82

The company has a wealth of resources to tap into that can enable it to pursue more acquisitions in the future or simply reinvest in its current operations. Alphabet has generated a staggering $160 billion in profit over the past four quarters. Its business is growing, and its margins are impressive. This is the type of low-risk growth stock that can also make for an excellent long-term investment.

The last $1,000 I'd reserve for a stock with a bit more risk but a ton of upside Now, with a couple of solid blue chip stocks in Alphabet and Enbridge, I can feel comfortable in taking on a bit more risk with the remaining $1,000. While I still don't want to gamble on highly speculative investments, I do want to focus on a much smaller business that may have significant growth potential.

For this stock, I'd choose CRISPR Therapeutics (CRSP +1.88%). CRISPR has a market cap of $5 billion and could be much more valuable in the future. It and its development partner, Vertex Pharmaceuticals, have an approved gene-editing therapy, Casgevy, which is in its early stages of commercialization. Thus, CRISPR isn't as risky as smaller biotech stocks without any approved products. It also has over $2 billion in cash and short-term investments to help fund its day-to-day operations, and also enable it to invest in other gene-editing therapies.

Today's Change

(

1.88

%) $

1.00

Current Price

$

54.09

CRISPR remains unprofitable, but it has some enticing growth opportunities. And I'd feel confident that even under a worst-case scenario where I lose most or all of my money in CRISPR, I could make it back through my other investments on this list. By having strong pillars in place, you can take on some risk while knowing you won't put your overall portfolio in serious danger.

CRISPR Therapeutics AG (CRSP - Free Report) ended the recent trading session at $53.09, demonstrating a +2.06% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 1.22%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, lost 1.35%.

The stock of company has risen by 9.31% in the past month, leading the Medical sector's gain of 4.11% and the S&P 500's gain of 1.56%.

The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company is predicted to post an EPS of -$1.13, indicating a 12.4% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 million, showing a 733.26% escalation compared to the year-ago quarter.

CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.89 per share and revenue of $28.88 million. These results would represent year-over-year changes of +24.42% and +722.82%, respectively.

Investors should also pay attention to any latest changes in analyst estimates for CRISPR Therapeutics AG. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.26% higher. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 150, positioning it in the bottom 39% of all 250+ industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

CRISPR Therapeutics AG (CRSP - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned +8.3%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 1.1%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

CRISPR Therapeutics is expected to post a loss of $1.13 per share for the current quarter, representing a year-over-year change of +12.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -1.7%.

For the current fiscal year, the consensus earnings estimate of -$4.89 points to a change of +24.4% from the prior year. Over the last 30 days, this estimate has changed +4.3%.

For the next fiscal year, the consensus earnings estimate of $3.97 indicates a change of +18.9% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed -9.4%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For CRISPR Therapeutics, the consensus sales estimate for the current quarter of $7.42 million indicates a year-over-year change of +733.3%. For the current and next fiscal years, $28.88 million and $131.2 million estimates indicate +722.8% and +354.3% changes, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago.

Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

3 Biotech Stocks That Could Benefit from the Patent CliffCRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.

Speaking at a Bank of America fireside chat hosted by analyst Alec Stranahan, Kulkarni said the company’s first 11 years were centered on developing CASGEVY for sickle cell disease and beta thalassemia and bringing the therapy to patients. With that program now commercialized through partner Vertex, he said CRISPR Therapeutics is shifting more attention to a broader portfolio that includes cardiovascular, autoimmune, oncology and rare disease programs.

Get CRISPR Therapeutics alerts:

CRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsKulkarni said the company expects six assets to generate data in the next 12 to 18 months. He described the pipeline as including CTX310, an ANGPTL3-targeting program for LDL cholesterol and triglyceride reduction; zugo-cel, an allogeneic CAR T cell therapy being developed for autoimmune disease and oncology; CTX611, a long-acting siRNA approach to blood thinning; CTX340, a hypertension program targeting angiotensinogen; an Lp(a) program; and an alpha-1 antitrypsin rare disease program.

CASGEVY Launch Gains Momentum, CEO Says Kulkarni said CASGEVY’s commercial rollout is “gaining a lot of momentum,” though he emphasized that the launch differs from a typical pharmaceutical launch because of the time required between patient initiation, cell collection, manufacturing, infusion and revenue recognition.

CRSPR Stock Could Be Ready to Deliver on Its Massive PromiseHe said Vertex, which is leading commercialization, initiated about 100 patients in 2024, more than 300 patients in 2025 and has now initiated more than 500 patients. Kulkarni said the growth in patient initiations should translate into future revenue as patients move through the treatment funnel, though he noted there can be a lag of two to three quarters from initiation to revenue recognition.

“It’s a certainty that it all falls through because you’re not seeing patients drop out of the journey,” Kulkarni said. “It’s just a matter of time.”

Stranahan noted that CASGEVY generated $43 million in the first quarter. Kulkarni said CRISPR Therapeutics does not see major headwinds for the product at this stage and said Vertex is executing well on supply chain and patient handling. He said the company feels “comfortable about the trajectory of the product.”

Pediatric Label and Reimbursement Seen as Tailwinds Kulkarni pointed to several potential tailwinds for CASGEVY, including a pediatric label expansion. The current U.S. label covers patients ages 12 and older, and the company has submitted for an expansion to patients ages 5 and older. Kulkarni said treating younger patients could help prevent vascular and organ damage associated with disease progression.

He also said the pediatric expansion could bring more children’s hospitals into the treatment network, potentially increasing center activation and treatment velocity.

Outside the United States, Kulkarni said CASGEVY is the only available option in certain markets. He also highlighted a reimbursement agreement in Germany, describing it as a significant achievement given prior challenges faced by a competitor in that market.

Kulkarni also discussed “gentler conditioning” as a future potential expansion of CASGEVY’s life cycle. He said CRISPR Therapeutics has not provided guidance on when such an approach might be available, but said it could meaningfully broaden the addressable population if it achieves results comparable to the current busulfan conditioning regimen.

Cardiovascular Programs Target Large Markets On CTX310, Kulkarni said the company presented data last year showing reductions of approximately 50% in LDL cholesterol or triglycerides after treatment. He said the therapy uses lipid nanoparticle delivery and described the early safety profile as favorable, with limited and self-resolving liver enzyme elevations observed.

For homozygous familial hypercholesterolemia, Kulkarni said the regulatory bar could be relatively low if the therapy can show additional LDL reduction on top of agents such as PCSK9 inhibitors. For severe hypertriglyceridemia, he said CRISPR Therapeutics needs more patient data before engaging regulators on a potential registrational path.

Kulkarni also discussed CTX340, which targets angiotensinogen for hypertension. He said a gene-editing approach could provide consistent blood pressure reduction, in contrast to therapies that may wear off toward the end of a dosing period. He said reducing systolic blood pressure by 10 to 15 millimeters of mercury could be clinically meaningful, while still allowing physicians to adjust other medications.

Separately, Kulkarni said the company’s collaboration with Sirius Therapeutics on a Factor XI siRNA program reflects a “right tool for the job” approach. He said CRISPR Therapeutics does not want to permanently edit Factor XI because anticoagulation may be needed for defined periods or specific patient populations. He said the company sees potential indications including secondary stroke prevention, atrial fibrillation patients not eligible for DOACs and peripheral artery disease after revascularization.

Zugo-cel Advances in Autoimmune Disease and Oncology Kulkarni described zugo-cel as a potential best-in-class allogeneic CD19 CAR T therapy, citing what he called autologous-like efficacy with the convenience and cost-of-goods profile of an allogeneic product.

In oncology, he said CRISPR Therapeutics previously showed a nearly 70% complete response rate, with at least two patients beyond 12 months at the time of the data cut. The company is also studying zugo-cel in combination with the BTK inhibitor pirtobrutinib, based on evidence that BTK inhibitors may potentiate CAR T therapies.

In autoimmune disease, Kulkarni said the company’s goal is to become a leading player. CRISPR Therapeutics has dosed patients in lupus, myositis and scleroderma through the AID-500 trial and has expanded into immune thrombocytopenia and warm autoimmune hemolytic anemia. He said the company has also opened an IND for neuroimmune indications, citing evidence that zugo-cel can enter the central nervous system and eliminate B cells in the spine or brain.

Kulkarni said CRISPR Therapeutics had dosed 14 patients in its autoimmune program as of its first-quarter update and expects to provide additional updates as development progresses.

About CRISPR Therapeutics NASDAQ: CRSPCRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in CRISPR Therapeutics Right Now?Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

CRISPR Therapeutics AG (CRSP - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this company have returned -15.8%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 7.8%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, CRISPR Therapeutics is expected to post a loss of $1.12 per share, indicating a change of +13.2% from the year-ago quarter. The Zacks Consensus Estimate has changed +5.7% over the last 30 days.

The consensus earnings estimate of -$5.08 for the current fiscal year indicates a year-over-year change of +21.5%. This estimate has changed -3.2% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $4.37 indicates a change of +14.1% from what CRISPR Therapeutics is expected to report a year ago. Over the past month, the estimate has changed +4%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, CRISPR Therapeutics is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of CRISPR Therapeutics, the consensus sales estimate of $8.08 million for the current quarter points to a year-over-year change of +808.1%. The $34.6 million and $129.51 million estimates for the current and next fiscal years indicate changes of +885.6% and +274.4%, respectively.

Last Reported Results and Surprise HistoryCRISPR Therapeutics reported revenues of $1.46 million in the last reported quarter, representing a year-over-year change of +67.8%. EPS of -$1.28 for the same period compares with -$1.58 a year ago.

Compared to the Zacks Consensus Estimate of $8.39 million, the reported revenues represent a surprise of -82.62%. The EPS surprise was -12.28%.

Over the last four quarters, CRISPR Therapeutics surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

CRISPR Therapeutics is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CRISPR Therapeutics. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

May 28, 2026 08:00 ET  | Source: CRISPR Therapeutics AG

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Time: 9:55 a.m. ET

William Blair’s 46th Annual Growth Stock Conference
Date: Wednesday, June 3, 2026
Time: 4:40 p.m. CT

Goldman Sach’s 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 2:40 p.m. ET

A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

Investor Contact:
+1-617-307-7503
[email protected]

Media Contact:
+1-617-315-4493
[email protected]

Many investors who follow CRISPR Therapeutics (CRSP +0.22%) still treat it as a gene-editing story. That makes sense, as the company's only commercialized drug, Casgevy, is a gene-editing therapy. But this biotech's ambitions are bigger than that modality alone.

In May 2025, it paid $95 million up front to Sirius Therapeutics for CTX611, a clinical-stage long-acting small interfering RNA (siRNA) therapy that's being investigated for the prevention of thrombosis and thromboembolic disorders. That often-overlooked program may turn out to be a major asset for the company; here's why.

Image source: Getty Images.

This program is an asymmetrical bet In a nutshell, CTX611 works by silencing the messenger RNA (mRNA) for the coagulation enzyme Factor XI in the liver. That silencing reduces the production of the coagulation factor, making the patient's blood less likely to form dangerous blood clots.

With CTX611, it may be possible to blunt the production of the coagulation factor without causing detrimental side effects like excessive bleeding, which is a problem with traditional anticoagulant medicines like warfarin. CRISPR Therapeutics' candidate is engineered for twice-yearly subcutaneous dosing, which may also be an advantage compared to alternatives that require daily pills or monthly antibody infusions.

One important thing to note is that CRISPR Therapeutics made a far smaller up-front commitment than its bigger competitors for a shot at the same market. Novartis paid up to $3.1 billion in 2025 to own abelacimab, a monthly antibody targeting the same coagulation factor. Eliquis, the leading anticoagulant (owned by Pfizer and Bristol Myers Squibb), alone generated $14.4 billion in revenue in 2025. While CRISPR Therapeutics owes Sirius additional milestone payments that could bring the deal's total value to over $800 million, and it'll also bear half of all development costs, that's still a fraction of what Novartis committed.

Today's Change

(

0.22

%) $

0.11

Current Price

$

50.34

There's a catch Competition in the anticoagulant segment is fierce and growing.

Aside from biologics being tested by players like Novartis, and improved small-molecule drugs (which build on the successes of the prior generation of those medicines) being tested by other big pharma businesses, CTX611 is not the only siRNA therapy targeting Factor XI. Suzhou Ribo Life Science's candidate, vortosiran, reached the clinic first, and is presently in phase 2b trials.

Even if CRISPR Therapeutics manages to get its program approved and out the door first, it'll immediately be competing intensely based on its therapy's cost, convenience, safety, availability, and effectiveness. The takeaway is that CTX611 is most likely to be a follower, rather than a category leader.

Nonetheless, given that the biotech only made $1.4 million in revenue in the first quarter of 2026 (though that figure excludes its 40% share of Casgevy revenue due to the way its collaboration is structured), even getting a foothold in the anticoagulants market with this candidate could be immensely impactful for the stock. The biotech expects to deliver an update on the program's progress through its phase 2 clinical trials in the second half of this year, so stay tuned.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, CRISPR Therapeutics, and Pfizer. The Motley Fool has a disclosure policy.